Zacks Research Downgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Hold

Monte Rosa Therapeutics (NASDAQ:GLUE) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other research firms have also recently commented on GLUE. Wedbush reiterated an “outperform” rating and set a $37.00 price objective on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price target (up from $27.50) on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 14th. Jefferies Financial Group reissued a “buy” rating and issued a $31.00 price objective on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Weiss Ratings restated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research report on Monday, December 29th. Finally, TD Cowen reiterated a “buy” rating on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Monte Rosa Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $31.33.

Monte Rosa Therapeutics Trading Down 3.2%

Shares of GLUE opened at $18.90 on Wednesday. Monte Rosa Therapeutics has a 12-month low of $3.50 and a 12-month high of $25.77. The stock has a market cap of $1.23 billion, a P/E ratio of 59.06 and a beta of 1.61. The company has a 50-day moving average of $19.22 and a two-hundred day moving average of $12.03.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.06. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%.The firm had revenue of $12.77 million for the quarter, compared to analyst estimates of $7.37 million. As a group, analysts forecast that Monte Rosa Therapeutics will post -1.49 EPS for the current fiscal year.

Insider Buying and Selling

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $23.49, for a total transaction of $128,396.34. Following the transaction, the chief executive officer owned 618,937 shares of the company’s stock, valued at $14,538,830.13. This trade represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 6.90% of the company’s stock.

Institutional Trading of Monte Rosa Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in GLUE. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Monte Rosa Therapeutics during the 3rd quarter worth about $379,000. Squarepoint Ops LLC acquired a new position in Monte Rosa Therapeutics during the second quarter valued at approximately $803,000. Allspring Global Investments Holdings LLC acquired a new position in Monte Rosa Therapeutics during the third quarter valued at approximately $182,000. Bailard Inc. purchased a new stake in Monte Rosa Therapeutics during the second quarter worth approximately $101,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Monte Rosa Therapeutics in the second quarter worth $89,000. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.